Clinical Trials · NCT05701241
Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients
- Phase
- Phase 4
- Recruitment status
- Recruiting
- Sponsor
- University Hospital, Antwerp
- Enrollment
- 270
- Start date
- Jun 2023
- Locations
- 19 sites, Belgium, Netherlands
- Primary endpoint
- the difference in progression-free survival (PFS) in patients continuing or stopping second-line therapy with SSAs, as assessed by the blinded local investigator on cross-sectional imaging, according to RECIST 1.1 criteria per substudy